About PhytoHealth

Incorporated in 1998, the PhytoHealth Corporation, a member of the Maywufa Biopharma Group, was the first drug development company listed on the Taiwan stock market.

PhytoHealth is pioneering novel drug development by innovating natural treatments used for thousands of years in traditional Chinese herbal medicine. By applying a “disease-targeted research model,” PhytoHealth expertly identifies plant and herb-based treatments that improve patients’ quality of life.

Since its inception, the founder, Mr. Lee Cheng-Chia, and his team have worked diligently to develop new drugs in compliance with international standards and regulations. Their meticulous work has resulted in key milestones, such as: PG2® Lyo. and Oraphine®  receiving TFDA approval PG2® Lyo., PHN031, PHN033 receiving US FDA approval for Phase II clinical trials The strength and outstanding performance of PhytoHealth’s R&D team have contributed to the company’s increasing value and recognition among investors.

To continuously drive success from development to market adoption, we follow three key tenants in all our work:

Beyond the development of new drugs, Phytohealth is dedicated to building a leading Asian biotech ecosystem. In 2016, PhytoHealth’s Botanical Active Pharmaceutical Ingredients (API) Manufacturing Factory obtained TFDA PIC/S GMP approval. The modern facility adheres to strict local guidelines and follows standards set by the US FDA. This step symbolizes a milestone in the new injectable botanical drug manufacturing technology in Taiwan’s domestic biotechnology industry.